Cytotoxic activity of the cluster rhenium compound with ?-alanine ligands

Polokhina, K. V.; Kytova, D. E.; Shtemenko, A. V.; Штеменко, Н. И.

doi:10.15407/ubj92.01.120

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High solubility of such substances in water, in contrast to alkylcarboxylates, greatly facilitates their use in physiological conditions. Also, I was shown to have cytotoxic and proapoptotic activity against Jurcat cells (Polokhina et al, 2020). The task of the work was to investigate anticancer activity of I in the model of tumor growth in vivo and to realize if the amino acid residue influences the DNA-binding activity of the amino acid derivatives of the cluster rhenium(III) compounds.…”

Section: Introductionmentioning

confidence: 99%

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

2020

The Journal of v. N. Karazin Kharkiv National University, Series "Biology"

View full text Add to dashboard Cite

Earlier we have shown that dirhenium(III) dicarboxylate complex with γ-aminobutyric acid possessed higher antitumor activity, than those of the previously investigated alkylcarboxylates, also may act as a modulator of cisplatin mechanism of action and as a stabilizer of red blood cells in tumor-bearing organisms. Thus, the task of the work was to investigate anticancer activity of the complex cis-[Re2(β-Ala)2Cl6] (I) in the model of tumor growth in vivo and to realize if the amino acid residue influences the DNA-binding activity of the amino acid derivatives of the cluster rhenium(III) compounds. Antitumor properties of the complex I were studied in the model of tumor growth with the use of Wistar rats inoculated by tumor carcinoma Guerink cells. The introduction of the compound alone in free and liposomal forms inhibited the tumor growth by 36 % and 45 % correspondingly, that is more than for dirhenium(III) clusters with alkyl ligands. The combined introduction of I and cisplatin had a significant impact on the tumor growth and showed the disappearance of the tumors in most of the animals. No considerable differences were found between introduction of liposomal and free form of I. The electronic absorption spectra of Calf Thymus DNA (CT-DNA) exhibit hyperchromism in the presence of increasing amounts of I. The DNA band at ~ 260 nm arises from the π-π* transitions of the nucleic acid bases and changes in the intensity and slight wavelength shifts of this characteristic band reflect the corresponding structural modifications of the DNA, which include changes in stacking, disruption of the hydrogen bonds between complementary strands, covalent binding of the DNA bases, intercalation of aromatic rings and others. The binding constant Kb(I) = 2.43 × 103 M-1 to CT-DNA was obtained that was lower than the values reported for the classical DNA intercalators and compares well with the magnitude of the binding constants for other complexes of dirhenium(III); titration of СT-DNA with cisPt and hydrogen peroxide also leads to a hypochromic effect, weak at low concentrations and more significant at high concentrations of I; the DNA binding constants increased in several times when using H2O2 or cisplatin that confirms a mechanism for redox activation of interaction of I with DNA in a cancer cell. The obtained results demonstrate the possibility of application of the amino acid derivatives of dirhenium(III) clusters in antitumor therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

2020

The Journal of v. N. Karazin Kharkiv National University, Series "Biology"

View full text Add to dashboard Cite

show abstract

Determination of the anticancer properties of cis- and trans-diadamanthylcarboxylates of dirhenium(III)

Штеменко

Polokhina

Golichenko

et al. 2020

SR: BS

View full text Add to dashboard Cite

The aim of the study. The aim of the work was to investigate in vivo anticancer activity of cis- and trans-diadamanthylcarboxylates of dirhenium(III) alone and together with cisplatin in form of nanobins.Materials and methods. Model of tumor growth, Guerin’s carcinoma; intraperitoneal administration of cisplatin, dirhenium(III) compounds in liposomes and of binary liposomes, containing both cytostatics; volumes and final weights of tumors were measured.Results. In vivo antitumor properties of two dirhenium(III) dicarboxylates with 1-adamantanecarboxylic acid moieties as ligands with cis- (I) and trans- (II) orientation of the carboxylic groups around a cluster fragment alone and together with cisplatin were presented; an attempt to understand differences in a possible mechanism of anticancer activity of the substances were undertaken. Antiradical and DNA-binding properties of I and II were the matter of consideration.Conclusions. Cis- and trans- compounds of dirhenium I and II had close antitumor activity in vivo with a little bit superiority of the cis- analog. Mechanisms of anticancer activity of I and II are different and may also include monofunctional adduct formation and subsequent interstrand cross-linking for the II substance, formation of protein-DNA cross-links, etc.

show abstract

Cytotoxic activity of the cluster rhenium compound with ?-alanine ligands

Cited by 2 publications

References 23 publications

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

Determination of the anticancer properties of cis- and trans-diadamanthylcarboxylates of dirhenium(III)

Contact Info

Product

Resources

About